IPHANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31Also trades as IPHYF

Innate Pharma SA

Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Apr 1, 2026

$1.46+0.03 (+2.10%)

Close on Oct 19, 2026

Innate Pharma SA income statement

AnnualQuarterlyTTM

EUR USD

Millions of EUR, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31	FY 2019 2019-12-31	FY 2018 2018-12-31	FY 2017 2017-12-31
Revenue	9.01	20	62	58	25	70	85	94	44
Research & Development	44	52	56	52	47	50	63	70	67
Selling, General & Admin	–	20	18	22	26	19	21	18	17
Selling & Marketing	0.52	0.35	0.37	0.66	0.47	0.50	0.59	0.52	0.65
Operating Expenses	63	72	74	115	73	69	84	88	84
Operating Income	-54	-52	-13	-57	-48	1.08	1.58	5.15	-40
Interest Expense	3.12	3.98	1.84	5.32	4.00	6.76	4.98	8.43	11
Interest & Investment Income	7.95	6.08	6.93	4.78	6.34	4.86	11	6.00	2.50
Pretax Income	-49	-49	-7.57	-58	-45	-0.83	7.87	2.72	-48
Income Tax Expense	0	0	0	0	0	0	0	-0.33	0.37
Income from Continuing Operations	-49	-49	-7.57	-58	-45	-0.83	7.87	–	–
Income from Discontinued Operations	–	0	0	-0.13	-7.33	-63	-29	–	–
Net Income incl. Noncontrolling Interests	-49	-49	-7.57	-58	-53	-64	-21	3.05	-48
EPS (Basic)(per share)	-0.55	-0.61	-0.09	-0.73	-0.66	-0.81	-0.31	0.05	-0.89
EPS (Diluted)(per share)	-0.55	-0.61	-0.09	-0.73	-0.66	-0.81	-0.31	0.05	-0.89
Shares Outstanding (Basic, Weighted)(shares)	90	81	80	80	80	79	67	59	54
Shares Outstanding (Diluted, Weighted)(shares)	90	81	80	80	80	79	67	59	54
EBITDA	-53	-50	-7.58	-12	-43	58	18	13	-36

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, FY2025

Gross margin: –
Operating margin: -599.8%
Net margin: –
Return on equity, FY2025: –

Financial strength

Current ratio: 0.60
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 19.7%

Valuation

P/E ratio: –
Price to sales: –
Price to book: –
Dividend yield: –

Valuation ratios need the share price and fill in once daily prices are connected.